deltatrials
Completed PHASE3 NCT00035815

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS)

Sponsor: ALS Association

Conditions Amyotrophic Lateral Sclerosis
Interventions Insulin like growth factor, type 1 Placebo
Updated 6 times since 2017 Last updated: Feb 13, 2013 Started: Jun 30, 2003 Primary completion: Aug 31, 2007 Completion: Dec 31, 2007

A PHASE3 clinical study on Amyotrophic Lateral Sclerosis, this trial is completed. The trial is conducted by ALS Association and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ALS Association
  • Cephalon
  • Mayo Clinic
  • National Institute of Neurological Disorders and Stroke (NINDS)
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States, Atlanta, United States, Cincinnati, United States, Cleveland, United States, Columbus, United States, Detroit, United States, Houston, United States, Indianapolis, United States, Jackson, United States, Jacksonville, United States and 9 more location s